BioAge Doses First Patient in Phase 2 DME Trial for Oral NLRP3 Inhibitor
BIOA has more than doubled off its 52-week low of $4.58 on light trading volume (0.4× avg).
Summary
BioAge has dosed the first participant in QUELL-DME, a Phase 2 trial of oral BGE-102 in diabetic macular edema. The ~180-patient study tests the drug as monotherapy and with anti-VEGF, with vision change at 12 weeks as the primary endpoint. This expands BGE-102 beyond the ongoing QUELL-CV cardiovascular trial, which has completed enrollment with data due in H2 2026. The DME readout is expected in H2 2027, so this is a pipeline milestone rather than a near-term catalyst. The stock remains sensitive to NLRP3 data after Novo Nordisk's ziltivekimab failure in July.
At the time of this announcement, BIOA was trading at $9.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $440.2M. The 52-week trading range was $4.58 to $25.96. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.